R&D,Clinical Development,Weekly Roundups,Biology

Weekly News Round-up – 9/4/21

4 months ago By Charlotte Di Salvo
  • Share on

  • Facebook
  • Linkedin

In the news this week, Genmab suggests potential investment plans for spin-off biotechs. In other news, alternative COVID-19 vaccines offered to under-30s, and Acadia fails to achieve FDA approval for psychosis drug. 

GENMAB CEO HINTS AT FUTURE INVESTMENT PLANS – CEO of Genmab, Jan van de Winkel, has suggested he would consider branching out with smaller, specialist biotech companies. The application of Genmab’s drugs in many fields, including autoimmune diseases, has shown potential to spin out smaller arms of the company in different disease areas, according to Van de Winkel. He stated he had ambitions for the company “to build an innovation powerhouse on our own.”

ALTERNATIVE COVID-19 VACCINE FOR THE YOUNGER POPULATION – After recent reviews by the Medicines and Healthcare Products Regulatory Agency (MHRA), under-30s in the UK will be offered alternative COVID-19 vaccines to the AstraZeneca jab. The final decision comes from the MHRA, with CEO Dr June Raine emphasising that the risks of the AstraZeneca vaccine were more ‘finely balanced’ with the benefits for the younger population.

ACADIA PSYCHOSIS DRUG DENIED FDA APPROVAL – Disappointment for Acadia as FDA rejects its psychosis drug, Nuplazid, for approval. Despite approval for the drug for Parkinson’s psychosis in 2016, the FDA denied approving Nuplazid for dementia-related psychosis. The decision came from the Division of Psychiatry, FDA, who inferred one of the reasons was that the “study data has had insufficient numbers of patients in the study with certain less common dementia subtypes.”

R&D
Artios Pharma and Novartis Collaboration Brings Hope for Next Generation Radioligand Therapy 

Manufacturing
EMA Classifies Blood Clot Risk of AstraZeneca COVID-19 Vaccine as ‘Very Rare Side Effect’ Linked with Low Blood Platelets 

Clinical
Eli Lily Fails to Reach End Goal with Arthritis Drug of Preventing Mechanical Ventilation in COVID-19 Patients

That’s all for now. See you next week!

Charlotte Di Salvo, Junior Medical Writer
Proventa International

More news

DeepMind’s AI Predicts Structures for More Than 350,000 Proteins

In 2003, researchers sequenced approximately 92% of the human genome, a huge achievement and very recently researchers have completed the entire process. Now, the latest innovation in AI technology has predicted the structure of nearly the entire human proteome. The...

7 days ago
R&D,Clinical Development,Weekly Roundups,Biology

DeepMind’s AI Predicts Structures for More Than 350,000 Proteins

In 2003, researchers sequenced approximately 92% of the human genome, a huge achievement and very recently researchers have completed the entire process. Now, the latest innovation in AI technology has predicted the structure of nearly the entire human proteome. The...

7 days ago

Rapid COVID Antibody Test Can Reveal Immune Status in 15 Minutes

As of July 2021, the number of hospitalisations and deaths due to COVID-19 have significantly dropped since the second peak around January this year. In addition to restrictions, the greatest contributor to this drop has been the rapid vaccine uptake...

1 week ago
R&D,Clinical Development,Weekly Roundups,Biology

Rapid COVID Antibody Test Can Reveal Immune Status in 15 Minutes

As of July 2021, the number of hospitalisations and deaths due to COVID-19 have significantly dropped since the second peak around January this year. In addition to restrictions, the greatest contributor to this drop has been the rapid vaccine uptake...

1 week ago

COVID-19 Booster Controversy: Disputes Across the Pharma Industry

Despite almost two thirds of the adult population in the UK having been vaccinated, cases are on the rise, which appear to be associated with the highly-transmissible delta variant of COVID-19. According to The European Centre for Disease Prevention and Control,...

2 weeks ago
R&D,Clinical Development,Weekly Roundups,Biology

COVID-19 Booster Controversy: Disputes Across the Pharma Industry

Despite almost two thirds of the adult population in the UK having been vaccinated, cases are on the rise, which appear to be associated with the highly-transmissible delta variant of COVID-19. According to The European Centre for Disease Prevention and Control,...

2 weeks ago
Working With us

Interested?
Reserve your space